Roche to acquire liver drug developer 89bio for up to $3.5 billion
Refinitiv1분 미만 읽기
Roche 
RO said on Thursday it agreed to acquire U.S. biotech firm 89bio
In a statement, the Swiss drugmaker said the deal was worth about $2.4 billion, or up to $3.5 billion when including a non-tradeable contingent value right.
이 뉴스를 읽으려면 로그인하거나 평생 무료 계정을 만드십시오